吲哚布芬治疗冠心病合并非瓣膜性心房颤动的效果及安全性  

Effect and safety of indobufen in the treatment of coronary heart disease complicated with non-valvular atrial fibrillation

作　　者：张鑫[1] 张化勇[1] 于仁亮[1] 刘玉红 韩立会 苏子德[1] ZHANG Xin;ZHANG Hua-yong;YU Ren-liang;LIU Yu-hong;HAN Li-hui;SU Zi-de(the Second People's Hospital of Liaocheng,Linqing 252600,China)

机构地区：[1]聊城市第二人民医院

出　　处：《临床医学研究与实践》2019年第20期22-24,共3页Clinical Research and Practice

摘　　要：目的探讨吲哚布芬在冠心病合并非瓣膜性心房颤动(NVAF)患者中的应用效果与安全性。方法将60例冠心病合并NVAF患者随机分为A、B、C三组,每组20例。三组患者均给以常规治疗,且A组服用吲哚布芬(100mg,2次/d),B组服用氯吡格雷(75mg,1次/d)和华法林(根据INR调整华法林用量),C组服用华法林,均进行为期6个月的观察。观察6个月后,统计比较三组患者的脑卒中发生率、心肌缺血改善情况以及药物不良事件总发生率。结果B组和C组各有1例患者因后期无法规律复查INR停服华法林并退出本研究。三组患者脑卒中发生率比较,差异无统计学意义(P<0.05)。A组心肌缺血无改善患者占比低于B组和C组,且B组低于C组(P<0.05)。A组的药物不良事件总发生率明显低于B组和C组(P<0.05)。结论吲哚布芬治疗冠心病合并NVAF患者能达到抗血小板和抗凝的双重目的,且不良反应更少,具有更好的临床安全性和依从性,值得推广应用。Objective To explore the application effect and safety of indobufen in the treatment of coronary heart disease complicated with non-valvular atrial fibrillation(NVAF).Methods Sixty patients with coronary heart disease complicated with NVAF were randomly divided into groups A,B and C,with 20 cases in each group.All the three groups were given routine treatment,and the group A was given indolebufen(100 mg,twice a day),the group B was given clopidogrel(75 mg,once a day)and warfarin(warfarin dosage adjusted according to INR),and the group C was given warfarin.All the three groups were observed for 6 months.After 6 months of observation,the incidence of stroke,improvement of myocardial ischemia and total incidence of adverse drug events were compared among the three groups.Results In the groups B and C,one patient stopped taking warfarin and dropped out of the study because of late failure to regularly review INR.There was no significant difference in the incidence of stroke among the three groups(P>0.05).The proportion of patients with no improvement of myocardial ischemia in the group A was lower than those in the groups B and C,and that in the group B was lower than the group C(P<0.05).The total incidence of adverse drug events in the group A was significantly lower than that of the groups B and C(P<0.05).Conclusion Indobufen in the treatment of coronary heart disease complicated with NVAF can achieve the dual purpose of anti-platelet and anti-coagulation,with fewer adverse reactions and better clinical safety and compliance.It is worthy of promotion and application.

关 键 词：吲哚布芬 冠心病 非瓣膜性心房颤动 氯吡格雷 华法林 

分 类 号：R541.4[医药卫生—心血管疾病] R541.75[医药卫生—内科学]